Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Steinberg

Showing results (381-390 of 481) with videos related to

Pageof 49
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancerMahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Pediatric Blood & Cancer|April 23, 2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, et al.
Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Blood|April 4, 2002
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson, Michael L Grossbard, Stefania Pittaluga, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 28, 2016
Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host DiseaseFilip Pirsl, Lauren M Curtis, Seth M Steinberg, et al.
Blood Advances|March 15, 2021
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseasesRamya Ramaswami, Kathryn Lurain, Mark N Polizzotto, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2011
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patientsOsama E Rahma, Ed Ashtar, Malgorzata Czystowska, et al.
Pageof 49

Showing results (381-390 of 481) with videos related to

Sort By:
Pageof 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancerMahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Pediatric Blood & Cancer|April 23, 2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, et al.
Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Blood|April 4, 2002
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson, Michael L Grossbard, Stefania Pittaluga, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 28, 2016
Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host DiseaseFilip Pirsl, Lauren M Curtis, Seth M Steinberg, et al.
Blood Advances|March 15, 2021
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseasesRamya Ramaswami, Kathryn Lurain, Mark N Polizzotto, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2011
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patientsOsama E Rahma, Ed Ashtar, Malgorzata Czystowska, et al.
Pageof 49